Fedratinib

• Description:

  Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].

• Product Name Alternative:

  TG-101348; SAR 302503

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; JAK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/TG-101348.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O

• Molecular Formula:

  C27H36N6O3S

• Molecular Weight:

  524.68

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13 (4) :311-20.|[2]Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13 (4) :321-30.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  JAK2

• Citation 01:

  Am J Clin Nutr. 2020 Jan 1;111 (1) :110-121.|Biomed Pharmacother. 2024 May:174:116447.|bioRxiv. 2024 May 6:2023.06.07.544058.|bioRxiv. 2024 Nov 5:2024.02.02.578646.|bioRxiv. 2024 September 24.|bioRxiv. 2025 February 21.|bioRxiv. 2025 Nov 26.|BMC Cancer. 2022 Aug 13;22 (1) :885.|Cancer Biol Ther. 2024 Dec 31;25 (1) :2432117.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Cell Prolif. 2020 Feb;53 (2) :e12742.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2024 Apr 25;187 (9) :2288-2304.e27.|EMBO Rep. 2019 Jun;20 (6) :e47202.|Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2023 Oct 19;125 (Pt A) :111087.|Int J Mol Sci. 2023 May 25;24 (11) :9243.|Invest Ophthalmol Vis Sci. 2024 Sep 3;65 (11) :21.|IUBMB Life. 2018 Jan;70 (1) :81-91.|J Exp Clin Cancer Res. 2025 Jan 2;44 (1) :2.|J Med Chem. 2021 Feb 25;64 (4) :2228-2241.|J Neuroinflammation. 2022 Oct 10;19 (1) :253.|J Pharm Sci. 2025 Feb;114 (2) :1444-1454.|Life Sci. 2023 May 15:321:121608.|Mol Cancer. 2021 May 29;20 (1) :80.|Mol Cancer. 2023 May 20;22 (1) :86.|Mol Cell Biochem. 2025 Apr;480 (4) :2645-2660.|Mol Pharm. 2017 Jan 3;14 (1) :274-283. |Mol Pharmacol. 2022 Jun;101 (6) :381-389.|Mol Ther Nucleic Acids. 2020 Sep 4;21:900-915. |Mol Ther Oncol. 2024 Jun 07.|Molecules. 2018 Aug 18;23 (8) . pii: E2071.|Nat Commun. 2025 Sep 29;16 (1) :8560.|Nature. 2023 Jun;618 (7963) :151-158.|Neuropsychiatr Dis Treat. 2020 Apr 1;16:891-900.|Patent. US20210128545A1.|Research Square Preprint. 2020 Jun.|Sci Rep. 2025 Jan 24;15 (1) :3124.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2020 Dec 26;5 (1) :295.|Signal Transduct Target Ther. 2022 Feb 23;7 (1) :52.|SSRN. 2025 Jul 4.|Toxicol Appl Pharmacol. 2024 Dec 24:495:117216.|University of California. Pharmaceutical Sciences and Pharmacogenomics. 2021 Apr.|University of Michigan. 2023 Sep.|University of Michigan. 2024.|University of Pennsylvania. 2025.|J Pharm Sci. 2025 Feb;114 (2) :1444-1454.

• CAS Number:

  936091-26-8